NAMS

NewAmsterdam Pharma Company N.V. is a biotechnology company operating in the healthcare sector. With a market capitalization of $3.80B and annual revenue of $35.24M, it represents a relatively large player within its industry. The company has a workforce of 68 employees. Financially, NewAmsterdam Pharma Company N.V. reports significant losses, with a net income of -$221,072,992 over the trailing twelve months. Its operating margin and profit margin are severely negative, at -15,845.7% and 0.0%, respectively. However, it maintains a robust cash position of $702.95M, which is offset by a debt of $266,000. The company's return on equity (ROE) and return on assets (ROA) are also negative, at -39.9% and -20.7%, respectively. The company's valuation metrics indicate a low price-to-book ratio of 5.20, as well as an extremely negative forward P/E ratio of -19.71. Its revenue growth over the past year is significant, with a decline of -98.8%. The dividend yield and payout ratio are not available for this company.